证券代码：688658 证券简称：悦康药业 公告编号：2025-032 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 悦康药业集团股份有限公司（以下简称"公司"）子公司北京悦康科创医药 科技股份有限公司（以下简称"悦康科创"）、杭州天龙药业有限公司（以下简 称"杭州天龙"）于近日获得国家药品监督管理局（以下简称"NMPA"）核准 签发的关于 YKYY029 注射液用于治疗高血压的《药物临床试验批准通知书》， 公司将开展本品 I 期临床试验。现将相关情况公告如下： 一、《药物临床试验批准通知书》主要内容： 1、药品名称：YKYY029 注射液 2、受理号：CXHL2500569 3、通知书编号：2025LP01808 4、申请适应症：高血压 5、申请人：北京悦康科创医药科技股份有限公司、杭州天龙药业有限公司 6、申报阶段：临床试验 悦康药业集团股份有限公司 关于自愿披露子公司 YKYY029 注射液获得国家药品 监督管理局临床试验批准的公告 YKYY029 注射液是悦康科创和杭州天龙自主开发的靶向 AGT 基因的小干 扰核 ...

证券代码：688658 证券简称：悦康药业 公告编号：2025-031 悦康药业集团股份有限公司 关于控股股东所持公司部分股份被第二次司法拍卖 的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、本次司法拍卖的基本情况 公司控股股东京悦永顺持有的公司 26,500,000 股无限售流通股股票于 2025 年 7 月 14 日 10 时至 2025 年 7 月 15 日 10 时止（延时除外）在京东网司法拍卖 网络平台（网址：http://sifa.jd.com/29 户名：北京市第二中级人民法院）上进行 司法拍卖。具体内容详见公司于 2025 年 6 月 28 日在上海证券交易所网站 （www.sse.com.cn）披露的《关于控股股东所持公司部分股份被第二次司法拍卖 的提示性公告》（公告编号：2025-030）。 二、本次司法拍卖的进展情况 根据京东网司法拍卖网络平台公示的《成交确认书》，本次网络拍卖竞价结 果如下： | 成交股数 | | --- | | | | | 司法拍卖 | | | 成交 ...

证券代码：688658 证券简称：悦康药业 公告编号：2025-031 悦康药业集团股份有限公司 关于控股股东所持公司部分股份被第二次司法拍卖 的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、本次司法拍卖的基本情况 公司控股股东京悦永顺持有的公司 26,500,000 股无限售流通股股票于 2025 年 7 月 14 日 10 时至 2025 年 7 月 15 日 10 时止（延时除外）在京东网司法拍卖 网络平台（网址：http://sifa.jd.com/29 户名：北京市第二中级人民法院）上进行 司法拍卖。具体内容详见公司于 2025 年 6 月 28 日在上海证券交易所网站 注 2：在网络拍卖中竞买成功的用户，必须依照标的物《竞买须知》、《竞买公告》要求， 按时交付标的物网拍成交余款、办理相关手续。最终成交以北京市第二中级人民法院出具的 拍卖成交裁定为准。 本次被司法拍卖的标的为悦康药业集团股份有限公司（以下简称"公司"） 控股股东阜阳京悦永顺信息咨询有限公司（以下简称"京悦永顺"）持 ...

Group 1 - The core viewpoint highlights the significant growth and performance of the Kexin Pharmaceutical ETF managed by Jiashi, with a notable increase in trading volume and fund size [2] - As of July 9, the Kexin Pharmaceutical ETF achieved a daily average trading volume of 34.95 million yuan over the past month, ranking first among comparable funds [2] - The fund's size increased by 16.76 million yuan in the past two weeks, also ranking first among comparable funds [2] - The ETF saw a total inflow of 12.84 million yuan over the last ten trading days, indicating strong investor interest [2] - The net value of the Kexin Pharmaceutical ETF rose by 36.83% over the past year, showcasing its strong performance [2] Group 2 - The top ten weighted stocks in the Shanghai Stock Exchange Science and Technology Innovation Board Biopharmaceutical Index account for 50.3% of the index, with leading companies including United Imaging Healthcare and BeiGene [2][4] - On July 9, Shanghai Pharmaceuticals announced an expected net profit of 4.45 billion yuan for the first half of 2025, representing a year-on-year increase of approximately 52% [4] Group 3 - Short-term market expectations for overseas transactions in innovative drugs are high, leading to a continuous rise in valuations [5] - China's innovative drug research and development capabilities are competitive globally, and the trend of innovative drugs going overseas is expected to persist [5] - The commercial health insurance sector in China is anticipated to see significant growth in premium income and payout rates, becoming an important source of funding for innovative drugs [5]

Investment Rating - The industry investment rating is "Positive" (maintained) [2] Core Insights - The report highlights the acquisition of Capstan Therapeutics by AbbVie for up to $2.1 billion, focusing on in vivo CAR-T therapy development [6][15] - The report emphasizes the growing interest and investment in in vivo CAR-T technology, with multiple companies actively pursuing diverse delivery systems [7][26] - The pharmaceutical and biotechnology sector saw a weekly increase of 3.64%, outperforming the CSI 300 index by 2.1 percentage points, ranking 4th among 31 sub-industries [8][31] Summary by Sections 1. AbbVie Acquisition of Capstan - AbbVie announced the acquisition of Capstan Therapeutics for a maximum of $2.1 billion, focusing on in vivo CAR-T therapies [6][15] - Capstan's main asset, CPTX2309, is an RNA delivery candidate for anti-CD19 CAR-T therapy, currently in Phase I clinical trials [15][20] 2. MNC's Active Layout in In Vivo CAR-T Technology - MNC has been actively investing in in vivo CAR-T technology through collaborations and acquisitions, focusing on both lentiviral and lipid nanoparticle delivery systems [7][26] - The report notes that over 20 disclosed mRNA technology projects in in vivo CAR-T are primarily concentrated in the lipid nanoparticle direction [22][30] 3. Weekly Performance of the Pharmaceutical Sector - The pharmaceutical sector increased by 3.64% in the first week of July, outperforming the CSI 300 index [31] - Among sub-sectors, other biological products saw the highest increase of 8.28%, while medical equipment experienced the largest decline of 0.21% [35][36] 4. Recommended Stocks - Recommended stocks include major pharmaceutical and biotechnology companies such as Heng Rui Medicine, East China Medicine, and others [9]

Group 1 - The core viewpoint of the news is that Yuekang Pharmaceutical Group has been recognized as one of the first batch of advanced intelligent factories in Beijing for 2025, highlighting its strong capabilities and leadership in the pharmaceutical intelligent manufacturing sector [1][2][3] - The selection process involved strict procedures including enterprise application, district recommendations, expert evaluations, and public announcements, establishing Yuekang as a benchmark for intelligent manufacturing in the industry [2] - Yuekang's intelligent manufacturing facilities feature advanced equipment and systems such as AI visual inspection, smart monitoring platforms, and a comprehensive digital management system that ensures quality and efficiency throughout the production process [2][3] Group 2 - Since 2011, Yuekang has consistently passed international certifications such as EU GMP and Japan JGMP, adhering to high standards in quality management [2] - In early 2024, Yuekang entered a comprehensive strategic partnership with Huawei to enhance its digital transformation, management system upgrades, and smart factory development, accelerating its transition to a "data-driven" enterprise [3] - The recognition as an advanced intelligent factory marks a significant milestone for Yuekang, which aims to continue investing in technological innovation to improve drug quality and contribute to the intelligent development of China's pharmaceutical industry [3]

Group 1: Core Insights - The collaboration between Ruijin Hospital and Huawei to open-source the RuiPath pathology model marks a significant milestone in China's AI healthcare sector, promoting open collaboration and inclusive development [1] - The RuiPath model covers seven major cancer types, addressing 90% of new cancer cases in China annually, and aims to enhance diagnostic efficiency and accuracy while reducing misdiagnosis [2][3] - The AI healthcare market in China is projected to grow from 8.8 billion yuan in 2023 to 315.7 billion yuan by 2033, with a compound annual growth rate of 43.1% [3] Group 2: Industry Trends - The AI healthcare sector is experiencing increased interest from investors, with seven AI healthcare stocks undergoing institutional research in the past month, focusing on core product development and collaborative models [4] - Companies like Sairui Medical and ZTE are integrating advanced AI technologies into their healthcare solutions, enhancing diagnostic capabilities and patient management [4][5] - The digital pathology remote diagnosis platform by Maxonic covers over 2,500 hospitals, accumulating more than 2 million digital pathology slice data, indicating a growing application of AI in tumor-assisted diagnosis [5]

Group 1 - The core point of the article is that Yuekang Pharmaceutical (688658) experienced a significant stock price increase of 15.55% on July 1, closing at 22.00 yuan, with a trading volume of 6.92 billion yuan and a turnover rate of 7.52% [2] - The stock was listed on the daily trading list due to its price increase exceeding 15% [2] - The top five trading departments accounted for a total transaction amount of 4.08 billion yuan, with a net buying amount of 1.71 billion yuan [2] Group 2 - Among the top five buying departments, three were institutional special seats, with buying amounts of 108.89 million yuan, 79.65 million yuan, and 50.55 million yuan respectively [2] - The leading selling department was Shenwan Hongyuan Securities, which sold 41.45 million yuan worth of shares [2] - The overall net inflow of main funds for the stock was 25.73 million yuan on that day [2]

（原标题：数据复盘丨医药生物、银行等行业走强 54股获主力资金净流入超1亿元） 7月1日，上证指数早盘探底回升，随后有所回落，临近午盘再度回升，午后震荡上扬；深证成指、创业板指早盘低开低走，午后震荡回升；科创 50指数全天震荡走低。截至收盘，上证指数报3457.75点，涨0.39%，成交额5535.57亿元；深证成指报10476.29点，涨0.11%，成交额9124.79亿 元；创业板指报2147.92点，跌0.24%，成交额4444.96亿元；科创50指数报994.80点，跌0.86%，成交额280.4亿元。沪深两市合计成交14660.36亿 元，成交额较上一交易日减少208.48亿元。 医药生物、银行等行业走强 诚邦股份4连板 盘面上来看，行业板块、概念涨多跌少。其中，医药生物、银行、教育、有色金属、公用事业、建筑材料、钢铁、化工等行业涨幅靠前；创新 药、可控核聚变、重组蛋白、维生素、合成生物、人脑工程、钛白粉、黄金、宠物经济等概念走势活跃。计算机、商贸零售、通信、传媒、证券 等行业跌幅居前；数字货币、跨境支付、铜缆高速连接、盲盒经济、国产软件等概念走势较弱。涨停个股主要集中在医药生物、化工、电子、机 械 ...

Group 1 - The 2025 BIO International Convention was held in Boston, attracting over 20,000 participants and more than 1,500 exhibitors, focusing on 18 key topics including AI and cell and gene therapies [1] - Yuyuan Pharmaceutical showcased its innovative pipeline in small nucleic acids and peptide drugs, highlighting its potential first-in-class and best-in-class projects [1] - The company presented its eleven leading technology platforms, emphasizing their core advantages and innovative layout in the nucleic acid and peptide fields [1] Group 2 - During the conference, Yuyuan Pharmaceutical engaged in in-depth discussions with major multinational corporations, Big Pharma, and renowned investment banks [2] - Several innovative drug projects, including YKYY015 (PCSK9 siRNA for high cholesterol), YKYY013 (HBV siRNA for hepatitis B), and YKYY025 (RSV mRNA vaccine), sparked significant interest due to their differentiated advantages [2] - The participation in the convention enhanced Yuyuan Pharmaceutical's international visibility and established a foundation for accelerating the international development and collaboration of its research pipeline [2]